Mylan

Raymond James 40th Annual Institutional Investors Conference

March 05, 2019

Mylan

Better Health for a Better World®

Forward-Looking Statements

This presentation contains “forward-looking statements.” These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, our 2019 financial guidance and any other statements about Mylan’s future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods. These may often be identified by the use of words such as “will,” “may,” “could,” “should,” “would,” “project,” “believe,” “anticipate,” “expect,” “plan,” “estimate,” “forecast,” “potential,” “pipeline,” “intend,” “continue,” “target,” “seek” and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; failure to achieve expected or targeted future financial and operating performance and results; uncertainties regarding future demand, pricing and reimbursement for our products; any regulatory, legal or other impediments to Mylan’s ability to bring new products to market, including, but not limited to, where Mylan uses its business judgment and decides to manufacture, market and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an “at-risk launch”); success of clinical trials and Mylan’s ability to execute on new product opportunities; any changes in or difficulties with our manufacturing facilities, including with respect to our remediation and restructuring activities, supply chain or inventory or our ability to meet anticipated demand; the scope, timing and outcome of any ongoing legal proceedings, including government investigations, and the impact of any such proceedings on our financial condition, results of operations and/or cash flows; the ability to meet expectations regarding the accounting and tax treatments of acquisitions, including Mylan’s acquisition of Mylan Inc. and Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business; changes in relevant tax and other laws, including but not limited to changes in the U.S. tax code and healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any significant breach of data security or data privacy or disruptions to our information technology systems; the ability to protect intellectual property and preserve intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; the impact of competition; identifying, acquiring and integrating complementary or strategic acquisitions of other companies, products or assets being more difficult, time-consuming or costly than anticipated; the possibility that Mylan may be unable to achieve expected synergies and operating efficiencies in connection with strategic acquisitions, strategic initiatives or restructuring programs within the expected time-frames or at all; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions and global exchange rates; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and related standards or on an adjusted basis. For more detailed information on the risks and uncertainties associated with Mylan’s business activities, see the risks described in Mylan’s Annual Report on Form 10-K for the year ended December 31, 2018 and our other filings with the Securities and Exchange Commission (the “SEC”). You can access Mylan’s filings with the SEC through the SEC website at www.sec.gov or through our website, and Mylan strongly encourages you to do so. Mylan routinely posts information that may be important to investors on our website at investor.mylan.com, and we use this website address as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). The contents of our website are not incorporated into this presentation. Mylan undertakes no obligation to update any statements herein for revisions or changes after the date of this presentation.

Mylan's 2018 Highlights

Financial Results

- **$11.4B** Total Revenues with > 60% Generated Outside North America
- **$4.58** Adjusted EPS* vs $4.56 in 2017
- **$2.7B** Adjusted Free Cash Flow*
- > **$630M** of Debt Repayments

Scientific Achievements

- Advanced Our Biosimilar Strategy with Key Product Approvals:
  - Fulphila®, Biosimilar Neulasta® for both U.S. and Europe
  - Semglee™, Biosimilar Lantus® for Europe
  - Hulio®, Biosimilar Humira® for Europe
  - Ogivri®, Biosimilar Herceptin® for Europe
- Expanded Respiratory Product Portfolio Offerings with the FDA Approval of YUPELRI™

Access Accomplishments

- Secured Regulatory Approvals for Biosimilars in More than 65 Countries Since the Start of Our Program
- Expanded Pipeline Includes > 3,600 Products Under Development & Pending Approval
- Serving ~40% HIV+ Patients & ~60% of the World's HIV+ Children on Treatment with Our Products

2018 By Segment(1)



2018 By Product Type(1)



(1) 2018 Net Sales

*Adjusted metrics are non-GAAP financial measures. Please see the Appendix or investor.mylan.com for the most directly comparable U.S. GAAP financial measures and reconciliations of such non-GAAP financial measures to those GAAP measures.

Broadly Diversified Portfolio

Global



North America



Europe



Rest of World



Full Year 2018 Net Sales by Product Type

Mylan
Better Health for a Better World®

U.S. Gx Portfolio Net Sales

2017 **2018** **2019E**







Mylan
Better Health for a Better World®

2019 Financial Guidance Summary*

Total Revenues	**$11.5 - $12.5B**
Adjusted Gross Margins*	53.0 - 54.0%
Adjusted R&D* as % of Total Revenues	4.5 - 5.5%
Adjusted SG&A* as % of Total Revenues	21.0 - 22.0%
Adjusted EBITDA*	$3.3 - $3.9B
Adjusted Net Earnings*	$2.0 - $2.5B
Adjusted EPS*	**$3.80 - $4.80**
Capital Expenditures	$250 - $400M
Adjusted Free Cash Flow*	**$1.9 - $2.3B**
Adjusted Effective Tax Rate*	19.0 - 20.0%
Average Diluted Shares Outstanding	515 - 519M

2019 is All About Execution and Effectively Deploying Capital for the Future

- Continue to Invest in the Business for the Long-Term
- Continue to Delever and Maintain Investment Grade Credit Rating

*Adjusted metrics are non-GAAP financial measures. Please see the Appendix or investor.mylan.com for more information.

2019 Segment Net Sales Guidance

	Total Net Sales % Growth vs. 2018	Key Drivers
North America	***High-single Digits***	+ New Key Strategic Product Launches, Including Wixela™ InHub™ + Carryforward of 2018 Launches: • Fulphila®, Biosimilar Neulasta® • YUPELRI™ + Continued Uptake of Glatiramer Acetate − Lower Volumes and Pricing on Existing Products
Europe	***Mid-single Digits***	+ Global Key Brands, Including Dymista, Creon, Influvac, Betadine & OTC Portfolio + Biosimilars, Including • Hulio®, Biosimilar Humira® • Ogivri®, Biosimilar Herceptin® + Continued Uptake of Glatiramer Acetate
Rest of World	***Mid-single Digits***	+ Expanding Our Reach in China and Brazil + Continued Focus on Australia & Japan and ARV Franchise + Biosimilar Launches

Appendix

Non-GAAP Financial Measures

This presentation includes the presentation and discussion of certain financial information that differs from what is reported under U.S. GAAP. These non-GAAP financial measures, including, but not limited to, adjusted EPS, adjusted net cash provided by operating activities, adjusted free cash flow, capital expenditures and net of proceeds from sale of certain property, plant and equipment are presented in order to supplement investors' and other readers' understanding and assessment of the financial performance of Mylan N.V. ("Mylan" or the "Company"). In the Appendix, Mylan has provided reconciliations of such non-GAAP financial measures to the most directly comparable U.S. GAAP financial measures. Investors and other readers are encouraged to review the related U.S. GAAP financial measures and the reconciliations of the non-GAAP measures to their most directly comparable U.S. GAAP measures set forth below, and investors and other readers should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in accordance with U.S. GAAP.

2019 Guidance

Mylan is not providing forward looking guidance for U.S. GAAP reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items without unreasonable effort. These items include, but are not limited to, acquisition-related expenses, restructuring expenses, asset impairments, litigation settlements and other contingencies, including changes to contingent consideration and certain other gains or losses. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Unaudited; in millions)
Adjusted Net Earnings and Adjusted EPS

	Three Months Ended December 31,				Year Ended December 31,			
(in millions, except per share amounts)	**2018**		**2017**		**2018**		**2017**	
U.S. GAAP net earnings and U.S. GAAP diluted earnings per share	$ 51.2	$0.10	$244.3	$0.46	$ 352.5	$0.68	$ 696.0	$1.30
Purchase accounting related amortization (primarily included in cost of sales) [(a)]	551.5		454.8		1,833.9		1,529.7	
Litigation settlements and other contingencies, net	1.1		12.7		(49.5)		(13.1)	
Interest expense (primarily clean energy investment financing and accretion of contingent consideration)	8.7		10.1		39.7		47.3	
Clean energy investments pre-tax loss	20.1		(19.2)		78.7		47.1	
Acquisition related costs (primarily included in SG&A and cost of sales) [(b)]	4.0		12.6		21.4		72.8	
Restructuring related costs [(c)]	37.9		75.2		240.2		188.0	
Other special items included in:								
Cost of sales [(d)]	85.7		24.3		225.1		63.5	
Research and development expense [(e)]	17.9		27.8		118.2		117.7	
Selling, general and administrative expense [(f)]	10.5		(1.0)		43.7		11.7	
Other expense, net [(g)]	(0.1)		8.9		25.4		13.8	
Tax effect of the above items and other income tax related items	(118.8)		(85.2)		(564.5)		(329.7)	
Adjusted net earnings and adjusted EPS	$669.7	$1.30	$765.3	$1.43	$2,364.8	$4.58	$2,444.8	$4.56
Weighted average diluted ordinary shares outstanding	516.5		535.7		516.5		536.7	

(a) The increase in purchase accounting related amortization is primarily due to the increase in amortization expense as a result of the full impact of certain product rights acquisitions which occurred in 2017, and the current year impact of the 2018 product rights acquisitions. The year ended December 31, 2018 includes impairment charges of $224.0 million.

(b) Acquisition related costs incurred in 2017 and 2018 consist primarily of integration activities.

(c) For the year ended December 31, 2018, approximately $118.4 million is included in cost of sales, approximately $17.6 million is included in R&D and approximately $104.5 million is included in SG&A. Refer to Note 17 Restructuring included in Item 8 in the Annual Report on Form 10-K for the year ended December 31, 2018 for additional information.

(d) The three months and year ended December 31, 2018 include expenses for certain incremental manufacturing variances and site remediation activities as a result of the activities at the Company's Morgantown plant of $50.8 million and 155.8 million, respectively. The three months and year ended December 31, 2018 also include $22.6 million for costs related to the recall of Valsartan products.

(e) Adjustment primarily relates to non-refundable payments related to development collaboration agreements.

(f) The increase for the year ended December 31, 2018 is primarily related to bad debt expense of approximately $26.5 million primarily related to a special business interruption event for one customer.

(g) The increase for the year ended December 31, 2018 is primarily related to mark-to-market losses of investments in equity securities historically accounted for as available-for-sale securities and the cumulative realized gains on such investments.

Mylan N.V. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Unaudited; in millions)
Adjusted Net Cash Provided by Operating Activities

	Year Ended December 31,	
	2018	**2017**
U.S. GAAP net cash provided by operating activities	$2,341.7	$2,064.8
Add:		
Restructuring and related costs [(a)]	277.0	152.4
Corporate contingencies	194.2	582.2
Acquisition related costs	4.8	29.5
R&D expense	147.5	54.6
Adjusted net cash provided by operating activities	$2,965.2	$2,883.5
Add / (deduct):		
Capital expenditures	(252.1)	(275.9)
Proceeds from sale of certain property, plant and equipment	—	19.3
Adjusted free cash flow	$2,713.1	$2,626.9

(a) For the year ended December 31, 2018 includes approximately $155.8 million of certain incremental manufacturing variances and site remediation expenses as a result of the activities at the Company's Morgantown plant.

Better Health
for a Better World®